Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Mizuho Securities questions if the obesity trade for the sto...

Mizuho Securities questions if the obesity trade for the stock is nearing its end. Management's lack of bullishness on MariTide, and the lead of Eli Lilly and Novo, puts pressure on Amgen to stand out. Leerink downgraded Amgen due to high expectations from its weight loss drug R&D program.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more
Translate
Report
41K Views
Comment
Sign in to post a comment
    avatar
    Moomoo AI Official Account
    Your AI assistant for discovering investment opportunities.
    3224Followers
    0Following
    7989Visitors
    Follow